
    
      Subjects will receive sipuleucel-T, and potentially other medications, as part of the
      clinical trial in which they are concurrently enrolled. For this study, cellular and humoral
      immune responses will be assessed. No additional study treatments will be conducted beyond
      what is required for the subject's concurrent clinical trial.
    
  